Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
31 authors.
Shailendra Kumar MauryaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0003-1315-0422
Jenny A Jaramillo-Gómez *Department of Pathology, University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center, Aurora, Colorado.ORCID 0009-0005-6416-0948
Asad Ur Rehman *Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0001-8787-8630
Shailendra Kumar Gautam *Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-8959-1331
Mahek FatimaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0009-0000-1141-7213
Md Arafat KhanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-1861-5594
Mohd Ali Abbas ZaidiDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-5446-261X
Parvez KhanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-8566-0248
Laiba AnwarDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0001-6172-748X
Zahraa Wajih AlsafwaniDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0009-0006-1795-3598
Ranjana K KanchanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-9649-9488
Sameer MohiuddinDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0009-0005-3399-0420
Ramesh PothurajuDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-0216-2578
Raghupathy VengojiDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-6914-3048
Ramakanth Chirravuri VenkataDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0009-0005-9856-8570
Gopalakrishnan NatarajanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0009-0006-0883-3623
Rakesh BhatiaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0009-0008-9940-1790
Pranita AtriDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-0417-0256
NaveenKumar PerumalDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0001-7167-5716
Sanjib ChaudharyDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0001-9630-1235
Imayavaramban LakshmananDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0003-1733-2223
Sidharth MahapatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-2483-0610
Geoffrey A TalmonDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-4841-286X
Jesse L CoxDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-4590-7381
Lynette M SmithDepartment of Biostatistics, University of Nebraska Medical Center, College of Public Health, Omaha, Nebraska.ORCID 0000-0002-0836-9932
Juan A Santamaria-BarriaDepartment of Surgery, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-6132-7328
Apar Kishor GantiDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0003-3724-2671
Jawed Akhtar SiddiquiDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0003-1287-3004
Diana M CittellyDepartment of Pathology, University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center, Aurora, Colorado.ORCID 0000-0002-8392-0800
Surinder Kumar BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0001-9470-9317
Mohd Wasim NasserDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0003-2070-4972
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC MetastasisP01CA217798 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI THAYER, SARAH P · 2018 to 2022
$8.1M
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic CancerR01CA247471 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., JAIN, MANEESH · 2020 to 2024
$2.8M
Novel approach to attenuate small cell lung cancer growth and metastasisR01CA218545 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI NASSER, MOHD WASIM · 2018 to 2022
$2.6M
Mechanisms underlying pro-metastatic effects of estrogen in the brain nicheR37CA227984 · NCI · UNIVERSITY OF COLORADO DENVER · PI CITTELLY, DIANA M. · 2018 to 2024
$2.5M
Targeting MUC5AC mucin in breast cancer brain metastasisR01CA241752 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI NASSER, MOHD WASIM · 2021 to 2025
$2.3M
Connectivity mapping identified novel combination therapy for glioblastomaR01CA273319 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., SHONKA, NICOLE · 2022 to 2025
$2.2M
National Cancer Institute (NCI) P30CA046934National Cancer Institute (NCI) R01CA218545National Cancer Institute (NCI) R01CA247471National Cancer Institute (NCI) R37CA227984NCI NIH HHS P01 CA217798NCI NIH HHS P30 CA036727NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA218545NCI NIH HHS R01 CA241752NCI NIH HHS R01 CA247471NCI NIH HHS R01 CA273319NCI NIH HHS R37 CA227984U.S. Department of Defense (DOD) W81XWH-21-1-0640
6 · The paper itself
Abstract
purposeBreast cancer brain metastasis remains a significant clinical problem. Mucins have been implicated in metastasis; however, whether they are also involved in breast cancer brain metastasis remains unknown. We queried databases of patients with brain metastasis and found mucin 5AC (MUC5AC) to be upregulated and therefore sought to define the role of MUC5AC in breast cancer brain metastasis. EXPERIMENTAL
designIn silico dataset analysis, RNA-sequence profiling of patient samples and cell lines, analysis of patient serum samples, and in vitro/in vivo knockdown experiments were performed to determine the function of MUC5AC in breast cancer brain metastasis. Coimmunoprecipitation was used to unravel the interactions that can be therapeutically targeted.
resultsGlobal in silico transcriptomic analysis showed that MUC5AC is significantly higher in patients with breast cancer brain metastasis. Analysis of archived breast cancer brain metastasis tissue further revealed significantly higher expression of MUC5AC in all breast cancer subtypes, and high MUC5AC expression predicted poor survival in HER2+ breast cancer brain metastasis. We validated these observations in breast cancer brain metastatic cell lines and tissue samples. Interestingly, elevated levels of MUC5AC were detected in the sera of patients with breast cancer brain metastasis. MUC5AC silencing in breast cancer brain metastatic cells reduced their migration and adhesion in vitro and in brain metastasis in the intracardiac injection mouse model. We found high expression of cMET and CD44v6 in breast cancer brain metastasis, which increased MUC5AC expression via hepatocyte growth factor signaling. In addition, MUC5AC interacts with cMET and CD44v6, suggesting that MUC5AC promotes breast cancer brain metastasis via the cMET/CD44v6 axis. Inhibition of the MUC5AC/cMET/CD44v6 axis with the blood-brain barrier-permeable cMET inhibitor bozitinib (PLB1001) effectively inhibits breast cancer brain metastasis.
conclusionsOur study establishes that the MUC5AC/cMET/CD44v6 axis is critical for breast cancer brain metastasis, and blocking this axis will be a novel therapeutic approach for breast cancer brain metastasis.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. · full record | OpenQuestion